Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.

M, Kropff; HG, Baylon; J, Hillengass; T, Robak; R, Hajek; P, Liebisch; S, Goranov; C, Hulin; J, Bladé; T, Caravita; H, Avet-Loiseau; TM, Moehler; C, Pattou; L, Lucy; E, Kueenburg; A, Glasmacher; R, Zerbib; T, Facon

doi:10.3324/haematol.2011.044271

Public

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial.

Shared by NobleBlocks on Dec 1, 2011 • 12:00 AM UTC

Authors:

Kropff M

Baylon HG

Hillengass J

Abstract

Background Thalidomide has potent antimyeloma activity, but no prospective, randomized controlled trial has evaluated thalidomide monotherapy in patients with relapsed/refractory multiple myeloma.Design and methods We conducted an international, randomized, open-label, four-arm, phase III trial to c...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!